NCT00901225 · REGISTRY CONDITION SEARCH

Study of Plerixafor for Rescue of Poor Mobilizers in Autologous Stem Cell Transplant

Found through the registry condition index, not selected as a treatment recommendation. This discovery collection was restricted to studies with posted results.

Phase: PHASE2
Status at capture: COMPLETED
Registry last update: 2014-05-07

Plerixafor, administered at a dose of 240 ug/kg, potentiates the effect of granulocyte colony-stimulating factor (G-CSF) to increase peripheral blood progenitor cells in both healthy volunteers and cancer patients. Furthermore, in cancer patients, cells collected via apheresis using Plerixafor and G-CSF have been successfully transplanted. In December 2008, Plerixafor received approval from the Food and Drug administration for use in combination with G-CSF to aid in mobilization of progenitor cells for apheresis. The proposed study is not designed to support approval of a new indication or change in the advertising for Plerixafor. The route of administration and dosage level are identical to that which is listed on the package insert. Although Plerixafor is not approved for patients with Hodgkins Lymphoma, there is no known or theoretic increased risk of the use of this drug in this patient population. The study hypothesis for this study is that patients with a circulating CD34+ count \< 20 cells/ul after 5 days of mobilization with G-CSF alone will achieve \> or equal to 2 X 10(6)CD34+ cells/kg within 3 days of apheresis after receiving Plerixafor with G-CSF.

Open the original ClinicalTrials.gov record → · Download preserved record

What did the study report?

Outcomes, safety and baseline populations are separate source sections. Quality-of-life measures appear under their original outcome titles.

flow

Participant flow

→

baseline

Baseline characteristics

→

outcome · POSTED

Number of Participants Who Achieved > or Equal to 2 X 10(6)CD34+ Cells/kg Within 3 Days of Apheresis After Receiving Plerixafor With G-CSF.

→

outcome · POSTED

Number of Participants Experiencing a Grade III/IV Toxicity

→

outcome · POSTED

Number of Subjects Experiencing Graft Failure

→

outcome · POSTED

Days to Absolute Neutrophil Count >500

→

outcome · POSTED

Number of Subjects Experiencing Durability of Engraftment

→

outcome · POSTED

Platelet Engraftment

→

adverse events

Adverse events

→

more info

Limitations, agreements, and source contact

→

Who could take part

eligibility Criteria: Inclusion Criteria: * Age 18 to 75 years. * Diagnosis of NHL, HD or MM * Eligible for autologous transplantation * CD34+ cell count \< 7 cells/ul after 5 days of mobilization with G-CSF or CD34+ cell count between 7 and 19 (inclusive) on day 5 of mobilization with G-CSF and \< 1.3 x 106 CD34+ cells collected by apheresis on day 5 of G-CSF therapy. * \< or equal to 5 prior regimens of chemotherapy (Rituxan is not considered chemotherapy for the purpose of this study) * ≥ 3 weeks since last cycle of chemotherapy and the beginning of G-CSF mobilization (Rituxan and Lenalidomide are not considered chemotherapy for the purpose of this study) * Total dose of melphalan \< or equal to 200 mg * ECOG performance status of 0 or 1 * Recovered from all acute toxic effects of prior chemotherapy * Absolute PMN count \> 1.0 X 10(9)/l prior to first dose of G-CSF * PLT count \> 75 X 10(9)/l prior to first dose of G-CSF * Serum creatinine \< or equal to 2.5 mg/dl * SGOT, SGPT and total bilirubin \< 2 X upper limit of normal (ULN) prior to the first dose of G-CSF * Cardiac and pulmonary status sufficient to undergo apheresis and transplantation as determined by standard institutional practice * Signed informed consent * Patients of childbearing potential agree to use an approved form of contraception Exclusion Criteria: * A co-morbid condition which, in the view of the investigator, renders the patient at high risk from treatment complications * Failed previous stem cell collection or collection attempts * A residual acute medical condition resulting from prior chemotherapy * Active brain metastases or carcinomatous meningitis * Active infection requiring antibiotic treatment (excluding controlled catheter-related bacteremia) * Received prior radio-immunotherapy with Zevalin or Bexxar * Received thalidomide, dexamethasone, and/or Velcade within 7 days prior to the first dose of G-CSF * Positive pregnancy test in female patients * Lactating females * Patients who previously received experimental therapy within 4 weeks of enrolling in this protocol
healthy Volunteers: false
maximum Age: 75 Years
minimum Age: 18 Years
sex: ALL
std Ages: ADULT
OLDER_ADULT

Treatment arms and interventions

arm Groups

description
Patients who were unable to mobilize a minimum number of cells (CD34+ cell count \<20 cells/ul)following 5 days of G-CSF mobilization.
intervention Names
Drug: G-CSF plus Plerixafor
label
G-CSF plus Plerixafor
type
EXPERIMENTAL

interventions

arm Group Labels
G-CSF plus Plerixafor
description
On Day 5 of G-CSF mobilization, 1. if the patient's peripheral CD34+ cell count is \< 7cells/µl then 240ug/kg Plerixafor will be given in the evening prior to receiving 10µg/kg G-CSF and undergoing apheresis the next morning for up to 3 days of apheresis or until ≥ 5x10(6) cells/kg are collected. 2. if the patient's peripheral CD34+ cell count is 7 to 19 cells/ul (inclusive), apheresis will be done. If the apheresis yield is \< 1.3x10(6) CD34+ cells/kg then 240ug/kg Plerixafor will be given in the evening prior to receiving 10 µg/kg G-CSF and undergoing apheresis the next morning. If the apheresis yield is at least double that on Day 5, Plerixafor followed the next morning by G-CSF and apheresis will be repeated for up to a total of 3 days of apheresis or until 5x10(6) cells/kg are collected.
name
G-CSF plus Plerixafor
other Names
Mozobil, AMD3100
type
DRUG

Study design

allocation

intervention Model

SINGLE_GROUP

masking Info

masking: NONE

primary Purpose

TREATMENT

Enrollment

count: 21
type: ACTUAL

Registered outcome plans (not posted results)

primary Outcomes

measure
Number of Participants Who Achieved > or Equal to 2 X 10(6)CD34+ Cells/kg Within 3 Days of Apheresis After Receiving Plerixafor With G-CSF.
time Frame
5 days after receiving G-CSF

secondary Outcomes

description
Safety of plerixafor as measured by Grade III/IV Toxicity
measure
Number of Participants Experiencing a Grade III/IV Toxicity
time Frame
6 months post transplant or until relapse
description
To investigate the hematological activity of Plerixafor as measured by Graft Failure. Graft failure is defined as failure of initial engraftment (primary graft failure) or initial engraftment, but subsequent loss of hematopoiesis (secondary graft failure).
measure
Number of Subjects Experiencing Graft Failure
time Frame
12 months
measure
Days to Absolute Neutrophil Count >500
time Frame
12 months
description
Durability of engraftment is defined as the duration and stability of hematopoiesis following autologous transplantation. Subjects who experience durable engraftment have neutrophil counts greater than 500 and platelet counts greater than 20,000 within the specified time frame.
measure
Number of Subjects Experiencing Durability of Engraftment
time Frame
12 months
description
Days to platelet count \>20,000
measure
Platelet Engraftment
time Frame
12 months

Full study description

brief Summary: Plerixafor, administered at a dose of 240 ug/kg, potentiates the effect of granulocyte colony-stimulating factor (G-CSF) to increase peripheral blood progenitor cells in both healthy volunteers and cancer patients. Furthermore, in cancer patients, cells collected via apheresis using Plerixafor and G-CSF have been successfully transplanted. In December 2008, Plerixafor received approval from the Food and Drug administration for use in combination with G-CSF to aid in mobilization of progenitor cells for apheresis. The proposed study is not designed to support approval of a new indication or change in the advertising for Plerixafor. The route of administration and dosage level are identical to that which is listed on the package insert. Although Plerixafor is not approved for patients with Hodgkins Lymphoma, there is no known or theoretic increased risk of the use of this drug in this patient population. The study hypothesis for this study is that patients with a circulating CD34+ count \< 20 cells/ul after 5 days of mobilization with G-CSF alone will achieve \> or equal to 2 X 10(6)CD34+ cells/kg within 3 days of apheresis after receiving Plerixafor with G-CSF.
detailed Description: This is a single-center, Phase 2, open-label study. All patients diagnosed with non-hodgkins lymphoma, hodgkins disease or multiple myeloma and candidates for autologous transplantation are eligible to enter into the study. The only change to the standard of care is the addition of 240 ug/kg Plerixafor following 5 days of (G-CSF) mobilization. The results of the study will provide both numeric and categorical estimates of measurements of the safety and efficacy of Plerixafor. The primary efficacy endpoint, Treatment Success, is a binary response variable categorizing whether the patient was able to mobilize at least 2 X 10(6) CD34+ cells/kg within 3 days of apheresis. The percentage of patients achieving Treatment Success will be summarized. All AEs will be followed for 30 days after the last apheresis or until the first dose of ablative chemotherapy, whichever occurs first. All SAEs will be followed for 6 months post-transplant or until relapse. All patients who receive at least one dose of Plerixafor will be included in all summaries of AEs.

Source references

Source notices and limitations

Discovery and provenance

release id
ctgov-registry-1336d216cbd1bbff780dac70
edge id
nct-edge-60600655bb4429a66fc1
requested nct id
NCT00901225
primary nct id
NCT00901225
source kind
ctgov_condition_query
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true
source record id
Source null
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
payload sha256
4f6e00776f9496a96bbc7395ccbeedeb02d85e1c8ee8a27f35ea75f890f05074
payload
clinical indication matching status
condition_index_match_asserted_by_registry_not_reviewed
end exclusive
true
id
nct-edge-60600655bb4429a66fc1
link basis
returned_by_explicit_condition_and_posted_results_filter_query
nct id
NCT00901225
occurrences
context exact
NCT00901225
end
11
exact text
NCT00901225
start
0
offset unit
unicode_code_points
query cond
Plasma Cell Neoplasms
query disease state id
ds-plasma-cell-neoplasms
source file
/Users/arunverma/Documents/ChatGPT/Cancer Statistics Website/research-data/2026-09-10/clinicaltrials-condition/round-0000/raw/cond-plasma-cell-neoplasms-000.json
source file sha256
2314ce01316b2d7044d298c6d25eda12e99cc5f44273bc75efed6cd5e03a8c14
source json pointer
/studies/534/protocolSection/identificationModule/nctId
source kind
ctgov_condition_query
source record id
Source null
source string basis
parsed_JSON_string_unmodified
source string sha256
a0fe531bd76f1263fadb997021fd2a7aba76755fd87bcb72fa5f0a4c355cf6ac
source url
https://clinicaltrials.gov/api/v2/studies?query.cond=Plasma+Cell+Neoplasms&filter.advanced=AREA%5BHasResults%5Dtrue&pageSize=1000&format=json&countTotal=true

Preserved source evidence · Not medical advice